Fig. 3From: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetesMeta-analysis evaluating the efficacy of SGLT-2i on MACE according to the age at entry in three trials (EMPA-REG, CANVAS and DECLARE)Back to article page